Atea Pharmaceuticals (AVIR) Change in Acquisitions & Divestments (2022 - 2026)

Atea Pharmaceuticals' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $104.3 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 49.92% year-over-year to $104.3 million in Q1 2026; TTM through Mar 2026 was $366.8 million, a 26.87% decrease from a year earlier, with the FY2025 full-year figure at $470.7 million, down 9.0% from the prior year.
• Change in Acquisitions & Divestments improved to $104.3 million in Q1 2026 per AVIR's latest filing, from $90.4 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $224.0 million in Q1 2024 and bottomed at $55.1 million in Q4 2024.
• The 5-year median for Change in Acquisitions & Divestments is $111.1 million (2024), against an average of $127.6 million.
• Across the five-year window, Change in Acquisitions & Divestments surged 64.02% in 2025 and plunged 49.92% in 2026, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $91.9 million in 2022, then decreased by 18.38% to $75.0 million in 2023, then fell by 26.53% to $55.1 million in 2024, then jumped by 64.02% to $90.4 million in 2025, then grew by 15.38% to $104.3 million in 2026.
• Per Business Quant, the three latest AVIR Change in Acquisitions & Divestments figures stand at $104.3 million (Q1 2026), $90.4 million (Q4 2025), and $56.1 million (Q3 2025).